TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Equities researchers at TD Cowen began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued to investors on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $44.00 price target on the stock. TD Cowen’s price objective would suggest a potential upside of 216.77% from the company’s previous close.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research report on Friday, January 10th.

Palvella Therapeutics Trading Up 7.1 %

PVLA opened at $13.89 on Wednesday. The company has a market cap of $155.85 million, a PE ratio of -1.15 and a beta of 0.68. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $22.32.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins acquired 4,000 shares of Palvella Therapeutics stock in a transaction on Wednesday, December 18th. The shares were bought at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the purchase, the director now owns 180,671 shares in the company, valued at $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.39% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.